share_log

赛诺菲安万特战略投资临床阶段生物技术公司

Gelonghui Finance ·  Jun 27 08:26
格隆汇6月27日|临床阶段生物技术公司Vigil Neuroscience表示,赛诺菲安万特以每股7.44美元的折算价格对该公司进行了4000万美元的战略投资。
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment